NASDAQ:ACLX - Arcellx Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $34.00
  • Forecasted Upside: 194.37 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$11.55
▲ +1.97 (20.56%)

This chart shows the closing price for ACLX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Arcellx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ACLX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ACLX

Analyst Price Target is $34.00
▲ +194.37% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Arcellx in the last 3 months. The average price target is $34.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 194.37% upside from the last price of $11.55.

This chart shows the closing price for ACLX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Arcellx.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/4/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/2/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/31/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/29/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/27/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/28/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/28/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/29/2022SVB LeerinkLower Price TargetOutperform$47.00 ➝ $44.00High
3/2/2022BarclaysInitiated CoverageOverweightMedium
3/1/2022William BlairReiterated RatingOutperformHigh
3/1/2022SVB LeerinkInitiated CoverageOutperform$47.00High
3/1/2022Bank of AmericaInitiated CoverageBuy$24.00High
(Data available from 5/28/2017 forward)

News Sentiment Rating

0.08 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/29/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/29/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/28/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/27/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
3/29/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
4/28/2022
  • 3 very positive mentions
  • 4 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
5/28/2022

Current Sentiment

  • 3 very positive mentions
  • 4 positive mentions
  • 5 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
Arcellx logo
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
Read More

Today's Range

Now: $11.55
Low: $9.90
High: $11.76

50 Day Range

MA: $11.44
Low: $7.21
High: $16.26

52 Week Range

Now: $11.55
Low: $6.03
High: $19.92

Volume

54,843 shs

Average Volume

120,634 shs

Market Capitalization

$412.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Arcellx?

The following equities research analysts have issued stock ratings on Arcellx in the last year: Bank of America Co., Barclays PLC, SVB Leerink LLC, and William Blair.
View the latest analyst ratings for ACLX.

What is the current price target for Arcellx?

0 Wall Street analysts have set twelve-month price targets for Arcellx in the last year. Their average twelve-month price target is $34.00, suggesting a possible upside of 194.4%.
View the latest price targets for ACLX.

What is the current consensus analyst rating for Arcellx?

Arcellx currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ACLX will outperform the market and that investors should add to their positions of Arcellx.
View the latest ratings for ACLX.

How do I contact Arcellx's investor relations team?

The company's listed phone number is 240-723-6641 and its investor relations email address is [email protected] The official website for Arcellx is arcellx.com. Learn More about contacing Arcellx investor relations.